{"transactions":[{"id":949728,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-05T21:30:21.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":false,"shares":19375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025."}],"balance_after":38750,"derivative":{"underlying":"Common Stock","underlying_shares":19375},"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":949727,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:30:21.000Z","date":"2025-12-31","kind":"grant","planned":true,"acquired":true,"shares":668789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 3 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met."},{"field":"shares","element":"transactionShares","label":"F4","text":"The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":668789,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":668789},"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":949726,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:30:21.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":7030,"price":0.6432,"value":4521.696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of 7,030 shares occurred automatically in a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":24766,"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":949725,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:30:21.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":true,"shares":19375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") convert to stock on a one-for-one basis."}],"balance_after":31796,"source":{"system":"sec-edgar","filing":"0001193125-26-002517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526002517/ownership.xml","form_type":"4"}},{"id":988284,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":300000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988283,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988282,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on August 3, 2023. The shares underlying the option began vesting on September 1, 2023 and continue to vest in equal monthly installments thereafter through August 1, 2027."}],"balance_after":150000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-08-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988281,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on August 3, 2023. The shares underlying the option began vesting on September 1, 2023 and continue to vest in equal monthly installments thereafter through August 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.75,"expiration_date":"2033-08-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988280,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":117000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":117000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988279,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":117000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":2.69,"expiration_date":"2032-12-31","underlying":"Common Stock","underlying_shares":117000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988278,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on September 1, 2022. The shares underlying the option began vesting on September 1, 2022 and continue to vest in equal monthly installments thereafter through August 1, 2026."}],"balance_after":20000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988277,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on September 1, 2022. The shares underlying the option began vesting on September 1, 2022 and continue to vest in equal monthly installments thereafter through August 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":2.13,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988276,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":45000,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988275,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026."}],"balance_after":0,"derivative":{"exercise_price":12.66,"expiration_date":"2032-02-21","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988274,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":37296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":37296,"derivative":{"exercise_price":1.5,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":37296},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988273,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":37296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":37296},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988272,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":23786,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":23786,"derivative":{"exercise_price":1.5,"expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":23786},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988271,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23786,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.65,"expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":23786},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988270,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":false,"shares":155090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":155090,"derivative":{"exercise_price":1.5,"expiration_date":"2031-03-28","underlying":"Common Stock","underlying_shares":155090},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988269,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":155090,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.65,"expiration_date":"2031-03-28","underlying":"Common Stock","underlying_shares":155090},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":988268,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:10:06.000Z","date":"2025-11-21","kind":"grant","planned":false,"acquired":true,"shares":925000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 8, 2025, the Board of Directors (the \"Board\") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the \"2025 Plan\"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as \"Tranche 1 Options\" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date."}],"balance_after":925000,"derivative":{"exercise_price":0.841,"expiration_date":"2035-10-07","underlying":"Common Stock","underlying_shares":925000},"source":{"system":"sec-edgar","filing":"0001193125-25-297204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525297204/ownership.xml","form_type":"4"}},{"id":1170759,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-04-16T20:30:14.000Z","date":"2025-04-15","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 15, 2025 and will vest in equal monthly installments beginning on May 1, 2025 through April 1, 2029."}],"balance_after":75000,"derivative":{"exercise_price":0.712,"expiration_date":"2035-04-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-25-010804","document":"form4-04162025_040404.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925010804/form4-04162025_040404.xml","form_type":"4"}},{"id":1313128,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:15:19.000Z","date":"2025-01-01","kind":"grant","planned":true,"acquired":true,"shares":251000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029."}],"balance_after":251000,"derivative":{"exercise_price":0.955,"expiration_date":"2035-12-31","underlying":"Common Stock","underlying_shares":251000},"source":{"system":"sec-edgar","filing":"0001415889-25-000407","document":"form4-01032025_040116.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925000407/form4-01032025_040116.xml","form_type":"4"}},{"id":1313127,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-03T21:15:19.000Z","date":"2025-01-01","kind":"exercise","planned":true,"acquired":false,"shares":19375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs) convert to stock on a one-for-one basis"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."}],"balance_after":58125,"derivative":{"underlying":"Common Stock","underlying_shares":19375},"source":{"system":"sec-edgar","filing":"0001415889-25-000407","document":"form4-01032025_040116.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925000407/form4-01032025_040116.xml","form_type":"4"}},{"id":1313126,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-01-03T21:15:19.000Z","date":"2025-01-02","kind":"sale","planned":true,"acquired":false,"shares":6954,"price":0.9837,"value":6840.6498,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of 6,954 shares occurred automatically in a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2024 solely to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":12421,"source":{"system":"sec-edgar","filing":"0001415889-25-000407","document":"form4-01032025_040116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925000407/form4-01032025_040116.xml","form_type":"4"}},{"id":1313125,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-03T21:15:19.000Z","date":"2025-01-01","kind":"exercise","planned":true,"acquired":true,"shares":19375,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs) convert to stock on a one-for-one basis"}],"balance_after":19375,"source":{"system":"sec-edgar","filing":"0001415889-25-000407","document":"form4-01032025_040116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588925000407/form4-01032025_040116.xml","form_type":"4"}},{"id":1439304,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-07T00:00:06.000Z","date":"2024-08-03","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on August 3, 2024 and will vest in equal monthly installments beginning on September 1, 2024 through August 1, 2028."}],"balance_after":52000,"derivative":{"exercise_price":0.895,"expiration_date":"2034-08-02","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001415889-24-020847","document":"form4-08062024_080802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588924020847/form4-08062024_080802.xml","form_type":"4"}},{"id":1527307,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-03T20:10:19.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":208000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028."}],"balance_after":208000,"derivative":{"exercise_price":1.08,"expiration_date":"2034-04-30","underlying":"Common Stock","underlying_shares":208000},"source":{"system":"sec-edgar","filing":"0001415889-24-012150","document":"form4-05032024_040504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588924012150/form4-05032024_040504.xml","form_type":"4"}},{"id":1690487,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Restricted Stock Units","published_at":"2024-01-03T21:38:17.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028."}],"balance_after":77500,"derivative":{"underlying":"Common Stock","underlying_shares":77500},"source":{"system":"sec-edgar","filing":"0001415889-24-000305","document":"form4-01032024_090105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588924000305/form4-01032024_090105.xml","form_type":"4"}},{"id":1801441,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF OPERATING OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-19T00:40:07.000Z","date":"2023-08-16","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date."}],"balance_after":300000,"derivative":{"exercise_price":2.785,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001415889-23-012417","document":"form4-08182023_080801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000141588923012417/form4-08182023_080801.xml","form_type":"4"}},{"id":1813564,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":70234,"kind":"person","name":"Frankenfield Christopher James","position":1,"cik":"0001988344","reported_name":"Frankenfield Christopher James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-07T20:12:19.000Z","date":"2023-08-03","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on August 3, 2023 and will vest in equal monthly installments beginning on September 1, 2023 through August 1, 2027."}],"balance_after":150000,"derivative":{"exercise_price":2.75,"expiration_date":"2033-08-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-23-088350","document":"tm2323038-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1840233/000110465923088350/tm2323038-2_4seq1.xml","form_type":"4"}}]}